Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.62 |
| ▸ | MAG | P20916 | 8/20 | 0.58 |
| ▸ | SELE | P16581 | 4/20 | 0.49 |
| ▸ | SELL | P14151 | 1/20 | 0.49 |
| ▸ | SELP | P16109 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29449201 | 0.96 | SIGLEC7 (0.66) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL21570085 | 0.91 | SIGLEC7 (0.62) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL28957980 | 0.91 | SIGLEC7 (0.62) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL28957979 | 0.91 | SIGLEC7 (0.62) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL29364999 | 0.91 | SIGLEC7 (0.62) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL21570084 | 0.91 | SIGLEC7 (0.62) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL23857822 | 0.90 | MAG (0.62) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL29361397 | 0.90 | MAG (0.62) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL29790139 | 0.89 | SIGLEC7 (0.63) | SIGLEC7MAGSELESELLSELP | |
| SCHEMBL29809799 | 0.89 | SIGLEC7 (0.63) | SIGLEC7MAGSELESELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651963-A1 | PURIFICATION OF AN OLIGOSACCHARIDE OR OLIGOSACCHARIDE MIXTURE | Inbiose N.V. (BE) | 2025-11-26 | — | — | EP | claimed |
| WO-2024153788-A1 | PURIFICATION OF AN OLIGOSACCHARIDE OR OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2024-07-25 | — | — | WO | claimed |
| EP-4731778-A2 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4702138-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | Inbiose N.V. (BE) | 2026-03-04 | — | — | EP | disclosed |
| EP-4662224-A1 | PRODUCTION OF A SACCHARIDE BY A CELL WITH REDUCED SYNTHESIS OF LACTOBIONIC ACID | Inbiose N.V. (BE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4651963-A1 | PURIFICATION OF AN OLIGOSACCHARIDE OR OLIGOSACCHARIDE MIXTURE | Inbiose N.V. (BE) | 2025-11-26 | — | — | EP | disclosed |
| EP-4652175-A1 | PURIFICATION OF A SACCHARIDE FROM A FERMENTATION BROTH | Inbiose N.V. (BE) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025206361-A1 | GENETICALLY MODIFIED MICROORGANISM AND METHOD FOR PRODUCING SUGAR | キリンホールディングス株式会社 | 2025-10-02 | — | — | WO | disclosed |
| EP-4608849-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | Inbiose N.V. (BE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4504920-A1 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024261312-A2 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2024-12-26 | — | — | WO | disclosed |
| WO-2022225779-A1 | METHODS AND COMPOSITIONS FOR PROMOTING WOUND HEALING | ABBOTT LABORATORIES (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-4077678-A1 | PRODUCTION OF SIALYLATED OLIGOSACCHARIDE IN HOST CELLS | Inbiose N.V. (BE) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022219187-A1 | CELLULAR PRODUCTION OF BIOPRODUCTS | INBIOSE N.V. (BE) | 2022-10-20 | — | — | WO | disclosed |
| US-11464793-B2 | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof | ABBOTT LABORATORIES (US) | 2022-10-11 | — | — | US | disclosed |
| WO-2022177965-A1 | NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES AND BOVINE IMMUNOGLOBULIN | ABBOTT LABORATORIES (US) | 2022-08-25 | — | — | WO | disclosed |
| US-11324765-B2 | Inhibiting inflammation with milk oligosaccharides | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220133758-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220119437-A1 | SYNTHESIS OF OLIGOSACCHARIDES | GLYCOM AS (DK) | 2022-04-21 | — | — | US | disclosed |
| EP-3980542-A1 | OPTIMAL CHROMOSOMAL INSERTION LOCI | Inbiose N.V. (BE) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324765-B2 | Inhibiting inflammation with milk oligosaccharides | FUT5, FUT6, ST3GAL3 | SIGLEC7 10/4885MAG 1011/4885SELE 112/4885 |
| US-20220133758-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS | FUT6, FUCA2, FUCA1 | SIGLEC7 86/4885MAG 1345/4885SELE 437/4885 |
| US-20220119437-A1 | SYNTHESIS OF OLIGOSACCHARIDES | MGAM, LCT, LPO | SIGLEC7 261/4885MAG 911/4885SELE 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.